☆ 4.5 Letter

Silexan for treatment of anxiety and depression in the context of COVID-19

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。
Review Clinical Neurology

Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis

Giovanna Fico et al.

Summary: This systematic review and meta-analysis investigates the repurposing of psychotropic drugs in the treatment of COVID-19. The study finds that antidepressants do not significantly affect the risk and mortality of COVID-19, while fluvoxamine may have potential in reducing mortality risk. Antipsychotics may increase the risk of severe COVID-19 and mortality, but their use in psychiatric patients should be evaluated on a case-by-case basis.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2023)

添加到收藏夹
Letter Clinical Neurology

Letter to the editor about the article Psychiatric disorders in post-acute COVID-syndrome 3 (PDPACS): Recommendations for health care professionals (Falconi A et al., 2022)

Cristian-Daniel Llach et al.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2022)

添加到收藏夹
Letter Clinical Neurology

Psychiatric disorders in Post-acute COVID-syndrome (PDPACS): Recommendations for health care professionals

Andrea Falconi Paez et al.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2022)

添加到收藏夹
Article Psychiatry

Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019

Alize J. Ferrari et al.

Summary: The Global Burden of Diseases Study in 2019 showed that mental disorders remained among the top ten leading causes of burden worldwide, with no reduction in burden since 1990. The majority of the burden in disability-adjusted life-years (DALYs) came from years lived with disability (YLDs).

LANCET PSYCHIATRY (2022)

添加到收藏夹
研讨会 海报 问题 讨论圈 基金 期刊 论文 科研社交 资讯集成 审稿人 关于我们 常见问题 移动App 隐私条款 使用条款
© Peeref 2019-2024. All rights reserved.